Valeant Adds 3 Directors, Including a Pershing Executive

Updated on
  • Investor Bill Ackman gets a board member at drugmaker
  • Other new members come from academia, pharmaceutical industry

Valeant CEO Meets With Top Execs After Medical Leave

Valeant Pharmaceuticals International Inc. will add three directors, including a representative from billionaire investor Bill Ackman’s investment firm, bolstering the board after facing criticism for its accounting and controversial distribution practices.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.